Pioneering Pathways
Explore Our Pathways to Innovation
Watch interviews with experts, Jazz Pharmaceuticals leaders, patients and advocates to learn more about our research to develop novel solutions to help improve the lives of people living with complex neurological conditions and difficult-to-treat cancers.
Trailblazing New Approaches in Idiopathic Hypersomnia and Beyond
Hear from the idiopathic hypersomnia community about living with this rare neurological disorder and how our work at Jazz Pharmaceuticals aims to provide treatment options informed by the needs of patients.
Scientist Spotlight: Gunjan Junnarkar on R&D in Idiopathic Hypersomnia
Hear from Gunjan Junnarkar, Vice President, Pharmaceutical Development and Manufacturing Science, on how Jazz Pharmaceuticals’ 20-year legacy in sleep disorder research aims to improve the lives of idiopathic hypersomnia patients.
Expanding What Is Possible in Targeted Oncology
Jazz Pharmaceuticals is determined to disrupt the status quo in targeted oncology by exploring breakthrough investigational molecules, including one that may expand the applicability of targeting the HER2 protein that is present in many solid tumor types. Learn more from some of our leaders in R&D as they work to make this a reality for patients in need.
“Developing novel ways to target specific proteins like HER2 may lead to improved standards of care in oncology, which is particularly needed for difficult-to-treat cancers, like those arising in the stomach or biliary tract. Due to their aggressive natures, these cancers present challenges for treatment and typically have poor prognoses for patients. I’m excited to be leading a team that’s developing an investigational treatment that targets these and other HER2-expressing solid tumor types.”
“Developing novel ways to target specific proteins like HER2 may lead to improved standards of care in oncology, which is particularly needed for difficult-to-treat cancers, like those arising in the stomach or biliary tract. Due to their aggressive natures, these cancers present challenges for treatment and typically have poor prognoses for patients. I’m excited to be leading a team that’s developing an investigational treatment that targets these and other HER2-expressing solid tumor types.”
– Elaina Gartner, Vice President Medical, Late-Stage Development, Oncology Clinical Development, Jazz Pharmaceuticals
We boldly create paths to new treatments for people living with complex diseases.
For more than 20 years, Jazz Pharmaceuticals has been at the forefront of pioneering innovative medicines for rare, hard-to-treat disorders. Pioneering Pathways homes in on the scientific exploration that is at the core of our growing expertise and groundbreaking discoveries in neuroscience and oncology.
Our Pipeline: Pioneering Innovative Science & Research
Get a behind-the-scenes look into Jazz Pharmaceuticals’ pipeline assets through educational animations around the proposed mechanisms of action of key neuroscience and oncology investigational assets.
Did You Know?
HER2 is a protein located in all cells that plays an important role in cell growth and survival. In certain cancers with solid tumors, HER2 can be produced in higher quantities, impacting patients’ overall prognosis. Currently, there are no approved targeted therapies for HER2 that can work across many tumor types. Learn more about the role of HER2 in one specific tumor type, biliary tract cancers.
Innovative Pathways in Post-Traumatic Stress Disorder Research
Millions of people worldwide are impacted by post-traumatic stress disorder (PTSD). Learn more about the proposed mechanism of action for fatty acid amide hydrolase (FAAH) inhibitors, currently being investigated in the underlying pathophysiology of PTSD.